Aktie 925692 EISAI CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Eisai Co., Ltd. OTC Markets

Aktien

925692

US2825793092

ESALY

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
FDA approves a second Alzheimer's drug that can modestly slow disease
Eli Lilly Alzheimer's drug approved by US FDA
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
Eisai Repurchases 4.8 Billion Yen Worth of Shares in June
Tranche Update on Eisai Co., Ltd.'s Equity Buyback Plan announced on May 15, 2024.
Japan's Eisai developing dementia drug for US market, Nikkei reports
EISAI - NEW EFFICACY DATA FOR NON-CLEAR CELL RENAL CELL CARCINOMA FROM KEYNOTE-B61 ADDED TO LENVIMA US LABEL SUPPORTING KEYTRUDA + LENVIMA INDICATION FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RCC
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
Eisai and Biogen launch Alzheimer's drug Leqembi in China
Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China
Leqembi[®] (lecanemab) launched in China
Periotherapia Co., Ltd. announced that it has received ¥390 million in funding from Mitsubishi UFJ Capital Co., Ltd., Eisai Co., Ltd., Techno Science, Inc., Chishima Real Estate Co., Ltd., Osaka University Venture Capital Co., Ltd.
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City
Eisai : Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
Biogen executive plays down looming competition for its Alzheimer's drug
BioArctic AB - FDA accepts filing of Leqembi sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease
Japan's Nikkei gains on chip shares boost; Fed policy in focus
Japan's Nikkei rises on US stocks, heavyweight chip shares
FDA advisory panel votes in favor of data for Lilly Alzheimer's drug
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 855526 Aktie
  4. 925692 Aktie
  5. Nachrichten Eisai Co., Ltd.
  6. Andere Sprachen